Andreas Von Deimling

Andreas Von Deimling's AcademicInfluence.com Rankings

Philosophy

#7285

World Rank

#10477

Historical Rank

Logic

#4342

World Rank

#5624

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Andreas Von Deimling's Degrees

Doctorate Medicine Heidelberg University
PhD Neuropathology Heidelberg University

Why Is Andreas Von Deimling Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Andreas Von Deimling's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary (2016) (11090)
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma (2012) (2074)
Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
DNA methylation-based classification of central nervous system tumours (2018) (1461)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor (2011) (1423)
Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas (2009) (1062)
Analysis of the IDH1 codon 132 mutation in brain tumors (2008) (971)
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma (2011) (871)
Dissecting the genomic complexity underlying medulloblastoma (2012) (777)
Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations (2012) (755)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas (2010) (714)
Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme (2006) (662)
Brain tumour cells interconnect to a functional and resistant network (2015) (655)
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma (2013) (637)
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs (2016) (608)
A vaccine targeting mutant IDH1 induces antitumour immunity (2014) (576)
Actively personalized vaccination trial for newly diagnosed glioblastoma (2018) (518)
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy (2014) (507)
Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma (2014) (496)
cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” (2018) (492)
Glioblastoma: pathology, molecular mechanisms and markers (2015) (482)
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody (2011) (456)
DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3–26.1 is deleted in malignant brain tumours (1997) (452)
The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma (2006) (449)
Instability of short tandem repeats (microsatellites) in human cancers (1994) (440)
MGMT testing—the challenges for biomarker-based glioma treatment (2014) (413)
Monoclonal antibody specific for IDH1 R132H mutation (2009) (393)
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma (2014) (367)
PTEN mutations in gliomas and glioneuronal tumors (1998) (366)
Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis (1993) (348)
ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis (2013) (298)
Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein (2013) (292)
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers (2015) (269)
Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma (2009) (261)
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system (2013) (254)
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas (2020) (253)
Molecular Genetic Evidence for Subtypes of Oligoastrocytomas (1997) (252)
Comparative Study of p53 Gene and Protein Alterations in Human Astrocytic Tumors (1993) (249)
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups (2015) (245)
IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma (2015) (243)
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma (2014) (243)
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO (2015) (241)
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas (2018) (236)
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities (2015) (230)
Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases (2012) (213)
Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma (2011) (211)
Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations (2013) (194)
Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets (2016) (188)
Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma (2014) (180)
Report of the committee on chromosome and gene loss in human neoplasia (1991) (174)
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression (2020) (170)
Brain metastases: pathobiology and emerging targeted therapies (2012) (168)
A role for β-melanocyte-stimulating hormone in human body-weight regulation (2006) (168)
Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells (2013) (158)
Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma (2018) (154)
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations (2018) (154)
Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity (2015) (145)
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas (2012) (144)
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo (2017) (135)
Downregulation of RUNX3 and TES by hypermethylation in glioblastoma (2007) (129)
Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes (2010) (128)
Methylation-based classification of benign and malignant peripheral nerve sheath tumors (2016) (126)
INI1 mutations in meningiomas at a potential hotspot in exon 9 (2001) (123)
Decreased hemispheric Aquaporin-4 is linked to evolving brain edema following controlled cortical impact injury in rats (2002) (123)
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology (2011) (123)
IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom (2012) (122)
H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers (2017) (121)
Loss of NF1 Alleles Distinguish Sporadic from NF1‐Associated Pilocytic Astrocytomas (2001) (120)
Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas (2015) (119)
Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative `tumor progression' locus (1997) (114)
Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (2016) (109)
Molecular pathogenesis of oligodendroglial tumors (2004) (108)
Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes (2008) (107)
Molecular Genetics of Pediatric Brain Stem Gliomas. Application of PCR Techniques to Small and Archival Brain Tumor Specimens (1993) (106)
Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma (2003) (105)
Nuclear relocation of STAT6 reliably predicts NAB2–STAT6 fusion for the diagnosis of solitary fibrous tumour (2014) (101)
BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma (2014) (100)
A highly conserved processed PTEN pseudogene is located on chromosome band 9p21 (1998) (99)
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy (2014) (95)
Neurofibromatosis Type 1: Pathology, Clinical Features and Molecular Genetics (1995) (94)
Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours (2006) (93)
PIK3CA mutations in glioblastoma multiforme (2005) (92)
Low Frequency of SV40, JC and BK Polyomavirus Sequences in Human Medulloblastomas, Meningiomas and Ependymomas (2000) (91)
Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation (2009) (91)
Diagnostic, prognostic and predictive relevance of molecular markers in gliomas (2015) (87)
Expression of αB‐crystallin in human brain tumors (1993) (85)
2‐Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size (2012) (85)
AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry (2013) (83)
Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors (2007) (81)
Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma (2013) (80)
Microsatellite analysis of loss of heterozygosity on chromosomes 9q, 11 p and 17p in medulloblastomas (1994) (79)
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat (2011) (78)
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial (2012) (78)
R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma (2011) (75)
Patterns of differentiation in central neurocytoma (1990) (73)
A rapid and non‐radioactive PCR based assay for the detection of allelic loss in human gliomas (1993) (71)
Biological and clinical heterogeneity of MYCN-amplified medulloblastoma (2012) (70)
Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas (1999) (70)
Chromosomal Imbalances in Brain Metastases of Solid Tumors (2000) (67)
Gliomatosis cerebri: no evidence for a separate brain tumor entity (2016) (67)
Hereditary Tumor Syndromes of the Nervous System: Overview and Rare Syndromes (1995) (65)
Estimating cancer survival and clinical outcome based on genetic tumor progression scores (2005) (64)
Deletions on the long arm of chromosome 17 in pilocytic astrocytoma (1993) (64)
Interlaboratory comparison of IDH mutation detection (2013) (63)
Melanotic Tumors of the Nervous System are Characterized by Distinct Mutational, Chromosomal and Epigenomic Profiles (2015) (62)
BRAF‐Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and CD34 Expression (2014) (62)
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas (2012) (61)
Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death (2013) (61)
Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain (2015) (57)
Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate (2012) (56)
Genetic Alterations Commonly Found in Diffusely Infiltrating Cerebral Gliomas Are Rare or Absent in Pleomorphic Xanthoastrocytomas (2002) (56)
NF2 Mutations in Secretory and Other Rare Variants of Meningiomas (2006) (55)
Pathology and molecular genetics of oligodendroglial tumors (2004) (53)
Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors (2004) (53)
BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts (2015) (53)
A Rapid and Sensitive Protocol for Competitive Reverse Transcriptase (cRT) PCR Analysis of Cellular Genes (1998) (52)
Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E (2014) (51)
MMP-13, p53 in the Progression of Malignant Peripheral Nerve Sheath Tumors (2007) (50)
Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q (2007) (50)
Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes (2010) (50)
Neuroradiology of central neurocytoma (2004) (47)
Attitude towards clinical trials: Results of a survey of persons interested in research (2004) (46)
Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). (2013) (46)
Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells (2007) (45)
Subclassification of Nerve Sheath Tumors by Gene Expression Profiling (2004) (45)
FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma (2018) (43)
A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16). (2016) (42)
BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma (2014) (40)
Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity (2014) (40)
Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms (2014) (40)
Clonality of multiple meningiomas (1997) (40)
Prognostic stratification of gliomatosis cerebri by IDH1R132H and INA expression (2011) (39)
Fibroblast Activation Protein–Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study (2021) (38)
Tryptophan‐2,3‐dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor‐4 (2016) (38)
Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment (2013) (38)
Diffuse glioneuronal tumour with oligodendroglioma‐like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14 (2019) (33)
Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants (2014) (32)
Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model (2010) (31)
Papillary Tumor of the Pineal Region: A Distinct Molecular Entity (2016) (31)
Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA (2019) (31)
Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities (2015) (30)
Evidence for Subarachnoid Spread in the Development of Multiple Meningiomas (1995) (29)
Expression of PACAP and glutamate transporter proteins in satellite oligodendrocytes of the human CNS (2007) (29)
Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo (2016) (28)
Radiotherapy plus concomitant temozolomide in primary gliosarcoma (2016) (28)
Analysis of TP53 and PTEN in gliomatosis cerebri (2003) (28)
Accumulation of genomic aberrations during clinical progression of medulloblastoma (2008) (27)
Amplification and overexpression of CMET is a common event in brain metastases of non‐small cell lung cancer (2014) (26)
Next Generation Sequencing and Pediatric Brain Tumors: Detection of Cancer Predisposition Syndromes in Patients and Their Families (2017) (26)
DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma (2017) (25)
Clonal Analysis in Glioblastoma with Epithelial Differentiation (2001) (24)
Cellular localization of pituitary adenylate cyclase-activating peptide (PACAP) following traumatic brain injury in humans (2007) (24)
Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia (2016) (24)
Rare mutations of the DMBT1 gene in human astrocytic gliomas (2002) (23)
Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature (2017) (23)
Differential nuclear ATRX expression in sarcomas (2016) (22)
Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens (2017) (21)
Pilocytic astrocytoma presenting as primary diffuse leptomeningeal gliomatosis: report of a unique case and review of the literature (2005) (21)
Abstracts for the committee on the genetic constitution of chromosome 1 (1991) (21)
Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer (2016) (21)
ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS (2018) (20)
Clonal Origin of Recurrent Meningiomas (1999) (19)
GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma (2020) (19)
Do host factors determine long-term survival in glioblastoma? A genome/transcriptome profiling study by the German Glioma Network. (2014) (19)
HDAC 5 and HDAC 9 in Medulloblastoma : Novel Markers for Risk Stratification and Role in Tumor Cell Growth (2010) (18)
NDRG1 prognosticates the natural course of disease in WHO grade II glioma (2014) (18)
Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death (2007) (17)
Rint1 inactivation triggers genomic instability, ER stress and autophagy inhibition in the brain (2015) (17)
Molecular characterization of medulloblastomas with extensive nodularity (MBEN) (2018) (15)
Corrigendum: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma (2012) (15)
Proteomics in Pathology (2018) (15)
Blood BRAFV 600 E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis (2012) (15)
A new approach to the molecular basis of neoplastic transformation in the brain (1992) (13)
Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zülch, the WHO… and Shakespeare (2017) (13)
Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis (2015) (13)
GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma. (2018) (12)
Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas (2009) (12)
FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas (2019) (11)
The mTOR target NDRG 1 confers MGMT-dependent resistance to alkylating chemotherapy (2017) (11)
Mutation analysis of DKK1 and in vivo evidence of predominant p53-independent DKK1 function in gliomas (2005) (11)
Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas (2016) (11)
Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients (2018) (11)
Phase I/II study of cetuximab plus temozolomide as radiochemotherapy for primary glioblastoma (GERT)—Eudract number 2005–003911–63; NCT00311857 (2008) (11)
Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker (2019) (10)
Histone epiproteomic profiling distinguishes oligodendroglioma, IDH-mutant and 1p/19q co-deleted from IDH-mutant astrocytoma and reveals less tri-methylation of H3K27 in oligodendrogliomas (2019) (10)
The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups. (2020) (10)
Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II (2008) (10)
MAP kinase activity supported by BRAFV600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases (2014) (9)
GRHL 1 Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC 3 (2013) (9)
Frame-based stereotactic biopsies using an intraoperative MR-scanner are as safe and effective as conventional stereotactic procedures (2018) (9)
Abstracts for the committee on comparative gene mapping (1991) (9)
Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma. (2015) (9)
Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature (2021) (9)
Farewell to oligoastrocytoma: response to letters (2014) (8)
Molecular genetic classification of astro cytic and oligodendroglial tumors (1997) (7)
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma (2019) (7)
Effect of an algorithm and patient information on serum phosphorus levels. (1984) (7)
Abstract 3687: An integrative genomics approach identifies distinct molecular and epigenetic subgroups of pediatric glioblastoma (2012) (7)
Identification of a novel selective inhibitor of mutant isocitrate dehydrogenase 1 at allosteric site by docking-based virtual screening (2016) (7)
The transcription factor Ets-1 is expressed in human amniochorionic membranes and is up-regulated in term and preterm premature rupture of membranes (2005) (7)
SCLEROSING EPITHELIOID MESENCHYMAL NEOPLASM OF THE PANCREAS A PROPOSED NEW ENTITY (2019) (7)
Characterization of the Human Rad 51 Genomic Locus and Examination of Tumors with 15 q 14 – 15 Loss of Heterozygosity ( LOH ) 1 (1999) (6)
Mutation and deletion analysis of GFRα-1, encoding the co-receptor for the GDNF/RET complex, in human brain tumours (1999) (6)
A role for b-melanocyte-stimulating hormone in human bodyweight regulation (6)
EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma. (2016) (6)
Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles (2019) (6)
p53 Accumulation Promotes Dephosphorylation and Proteolytic Cleavage of Retinoblastoma Protein in Human Malignant Glioma Cells (1997) (6)
Abstracts for the committee on the genetic constitution of the X chromosome (Part 3 of 3) (1991) (5)
Impact of post-surgical freezing delay on brain tumor metabolomics (2019) (5)
Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N²M²). (2016) (5)
Abstracts for the committee on the genetic constitution of chromosome 17 (1991) (5)
RESULTS OF THE INTERNATIONAL INTERLABORATORY COMPARISON OF MGMT PROMOTER METHYLATION ANALYSIS INVOLVING TWENTY-THREE ACADEMIC CENTERS IN GERMANY, AUSTRIA AND THE NETHERLANDS (2014) (4)
Abstracts for the committee on the genetic constitution of chromosome 2 (1991) (4)
VXM01 phase I study in patients with progressive glioblastoma: Final results. (2018) (4)
[On the prognosis of hip fractures. Assessment of mortality after hip fractures by analyzing overlapping segments of longitudinal data]. (2005) (4)
Guidelines on the Management of Low-grade Gliomas: EANO Task Force Report (2012) (4)
Osteosarcoma: novel prognostic biomarkers using circulating and cell-free tumour DNA (2021) (4)
MOLECULAR GENETIC ALTERATIONS IN PEDIATRIC BRAIN STEM GLIOMAS (1993) (4)
45‐ YEAR‐OLD MALE WITH SYMPTOMATIC MASS IN THE FRONTAL LOBE (2006) (4)
Anendogenous tumour-promoting ligand of the human aryl hydrocarbon receptor (2011) (4)
[On general practitioners' care of patients with asthma]. (2012) (4)
Utilization of a MAB for BRAFV 600 E detection in papillary thyroid carcinoma (2012) (4)
Mapping pediatric brain tumors to their origins in the developing cerebellum (2021) (4)
NEXT-GENERATION NEUROPATHOLOGY - IMPROVING DIAGNOSTIC ACCURACY FOR BRAIN TUMORS USING DNA METHYLATION ARRAY-BASED MOLECULAR PROFILING (2014) (4)
Abstracts for the committee on the genetic constitution of chromosome 6 (1991) (4)
IMPS-14PROGNOSTIC ROLE OF REGULATORY T-CELLS IN PRIMARY AND RECURRENT MENINGIOMA. (2015) (3)
Abstracts for the committee on the genetic constitution of chromosome 15 (1991) (3)
Abstracts for the committee on chromosomal changes in neoplasia (1991) (3)
Abstracts for the committee on the genetic constitution of chromosome 12 (1991) (3)
Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial. (2014) (3)
DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome—including in elderly patients (2022) (3)
Biomarkers for malignant peripheral nerve sheath tumours. (2008) (3)
Erbitux® (Cetuximab) Plus Temozolomide as Radiochemotherapy for Primary Glioblastoma (GERT): Interim Results of a Phase I/II Study (2008) (3)
TP53 mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistance (2018) (3)
IDH1 mutant glioma initiating cells are predisposed to apoptosis under endoplasmic reticulum (ER) stress (2018) (2)
Abstract LB-80: ATRX loss refines the classification of anaplastic glioma and is a favorable prognostic marker. (2013) (2)
P01.013 Long-term analyses of the NOA-08 randomized phase III trial of temozolomide versus radiotherapy for elderly patients with malignant astrocytomas (2018) (2)
Reply to J.C. Lindsey et al (2011) (2)
An endogenous ligand of the human aryl hydrocarbon receptor promotes tumor formation (2017) (2)
VXM01 phase I study in patients with resectable progression of a glioblastoma. (2017) (2)
Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma. (2014) (2)
CELL BIOLOGY AND SIGNALING (2010) (2)
Molecular progression of SHH-activated medulloblastomas (2019) (2)
Efficacy of re-irradiation with carbon ions (RiCi) in patients with recurrent high-grade glioma (rHGG) compared to the standard re-irradiation with photons (RiP): The reference multicenter cohort of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). (2019) (2)
BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications (2012) (2)
GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS (2019) (2)
Identification of New Inhibitors of Mutant Isocitrate Dehydrogenase 2 through Molecular Similarity-based Virtual Screening (2019) (2)
Cerebral metastases of a dermatofibrosarcoma protuberans (2019) (2)
Radiochemotherapy with daily concomitant and adjuvant one week on/one week off temozolomide plus indomethacin in newly diagnosed glioblastoma: A phase II trial (2008) (2)
Impact of the New WHO Classification on Decision-making for Radiation Therapy in Patients with Atypical and Anaplastic Meningiomas (2009) (2)
Differential patterns of molecular genetic alterations define subsets among glioblastomas and oligoastrocytomas (1998) (2)
Abstracts for the committee on the genetic constitution of chromosome 16 (1991) (2)
Abstracts for the committee on the genetic constitution of chromosome 22 (1991) (2)
PDCT-05. MOLECULAR DIAGNOSTICS REVEAL 60% HIGHER SURVIVAL FOR MOLECULARLY-VERIFIED VERSUS HISTOPATHOLOGICALLY-DIAGNOSED PEDIATRIC SUPRATENTORIAL CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS AND PINEOBLASTOMAS; A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP ACNS0332 TRIAL (2017) (2)
Solides kraniopharyngeom im III. Ventrikel - Differential-diagnostische aspekte (1998) (2)
PROGNOSTIC AND PREDICTIVE BIOMARKER-BASED SUBGROUPS IN THE NOA-04 TRIAL (2014) (2)
Clinical Epidermal Growth Factor Receptor Variant III ( EGFRvIII ) Positivity in EGFR-Ampli fi ed Glioblastomas : Prognostic Role and Comparison between Primary and Recurrent Tumors (2017) (2)
Abstracts for the committee on the genetic constitution of chromosome 11 (1991) (2)
Abstract 2645: BAY 1436032: A highly selective, potent and orally available inhibitor of mutant forms of IDH1 (2016) (2)
Validation of Prognostic Significance of IDH1 and MGMT in Patients with Glioblastoma: One Step Forward, and One Step Back? (2010) (2)
SPONTANEOUS IMMUNE RESPONSES IN GBM PATIENTS AFTER COMPLETE TUMOR RESECTION ARE ASSOCIATED WITH AN IMPROVED SURVIVAL (2014) (2)
MBCL-21. EARLY CHILDHOOD MEDULLOBLASTOMA: SUBGROUP-SPECIFIC SURVIVAL IN PATIENTS TREATED WITH SYSTEMIC CHEMOTHERAPY AND INTRAVENTRICULAR MTX TO AVOID CRANIOSPINAL RADIOTHERAPY (2018) (1)
P04.22OLIGOASTROCYTOMA DOES NOT EXIST: A MOLECULAR GENETIC REAPPRAISAL ON SINGLE-CELL LEVEL (2014) (1)
WHO Guidelines for Diagnosis of Glial Tumours : What Is Old and What Is New ? (2011) (1)
MCP-1 as an Effector of IL-31 Signaling in Familial Primary Cutaneous Amyloidosis (2013) (1)
OMICS AND PROGNSTIC MARKERS (2013) (1)
FAM131B-BRAF Fusion Gene Resulting From 7q34 Deletion Leads to MAPK Pathway Activation in Pilocytic Astrocytoma (2011) (1)
Long-term survival in primary glioblastoma revisited: The contribution of isocitrate dehydrogenase mutations. (2013) (1)
KS01.3.A Tumoral MHC class II expression in gliomas drives T cell exhaustion (2021) (1)
NIMG-02. NON-INVASIVE DETECTION OF IDH MUTANT 1p19q NON-CODELETED GLIOMAS USING THE T2-FLAIR MISMATCH SIGN (2019) (1)
P01.133 Preoperative predictors of malignancy in non-enhancing glioma in the era of molecular classification (2018) (1)
GENE-12. ANAPLASTIC NEUROEPITHELIAL TUMOR WITH CONDENSED NUCLEI (ANTCON): A NOVEL BRAIN TUMOR ENTITY WITH RECURRENT NTRK FUSION (2019) (1)
OS07.1 Molecular differences in IDH wild type glioblastoma according to MGMT promoter methylation status. (2017) (1)
Clinical and molecular features associated with long-term survival of elderly patients with glioblastoma. (2017) (1)
Abstracts for the committee on the genetic constitution of chromosome 7 (2004) (1)
Abstract 1424: KCNJ2 comprises a marker of poor prognosis and a therapeutic target in non-WNT/non-SHH medulloblastoma (2012) (1)
Abstract 3240: The Wnt secretion factor Evi/Wls/Gpr177 promotes glioma tumorigenesis (2012) (1)
Abstracts for the committee on the genetic constitution of chromosome 13 (1991) (1)
Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling. (2015) (1)
Abstracts for the committee on the genetic constitution of chromosome 10 (1991) (1)
ACTR-05. THE RANDOMIZED PHASE II ARTE TRIAL: BEVACIZUMAB PLUS HYPOFRACTIONATED RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2017) (1)
The INFORM personalized medicine study for high-risk pediatric cancer patients. (2017) (1)
DNA methylation array-based molecular profiling for brain tumor classification (2015) (1)
HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA (2016) (1)
fundiInhibition of CD95/CD95L Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma (2018) (1)
OS6.1 Molecular characterization of astroblastoma (2016) (1)
OS11.5.A PATZ1 fusions define a novel molecularly distinct CNS tumor entity with a broad histological spectrum (2021) (1)
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial ependymoma (2021) (1)
Abstracts for the committee on the genetic constitution of chromosome 4 (1991) (1)
Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity (2016) (1)
GRHL1 inhibits tumorigenicity and is a prognostic marker in neuroblastoma (2013) (1)
Machine Learning Improves Diagnosis of CNS Cancers. (2018) (1)
MNGI-13. A DNA METHYLATION-BASED CLASSIFIER FOR ASSESSMENT OF RISK OF RECURRENCE IN MENINGIOMA (2018) (1)
Abstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma (2016) (1)
OS2.1 Immune responses to a mutation-specific peptide vaccine targeting IDH1R132H in patients with IDH1R132H-mutated gliomas. (2016) (1)
Abstracts for the committee on the genetic constitution of the Y chromosome (1991) (1)
TB-11MOLECULAR NEUROPATHOLOGY 2.0 - INCREASING DIAGNOSTIC ACCURACY IN PEDIATRIC NEUROONCOLOGY (2016) (1)
Abstracts for the committee on the genetic constitution of chromosome 9 (1991) (1)
Abstract 1906: PFKFB4, much more than just a glycolytic gene (2018) (0)
Abstracts for the committee on the genetic constitution of chromosome 19 (1991) (0)
Identification of the Prognostic Signatures for Isocitrate Dehydrogenase Mutant Glioma (2022) (0)
SOCIETY NEWS (2006) (0)
GE-30OLIGOASTROCYTOMA DOES NOT EXIST: IN-SITU MOLECULAR GENETICS FAVORS CLASSIFICATION AS EITHER OLIGODENDROGLIOMA OR ASTROCYTOMA (2014) (0)
P02.03 Multiple sclerosis and gliomas - a coincidence? (2016) (0)
Histone deacetylases 5 and 9 are novel markers for medulloblastoma risk stratification and potential drug targets for therapy (2009) (0)
P01.031 VXM01 phase I study in patients with progressive glioblastoma - final results (2018) (0)
Abstract 3093: Unravelling the biology of aggressive and therapy-resistant embryonal tumors with multilayered rosettes (ETMR) (2014) (0)
Em-24. Telomerase Inhibition Induces Growth Arrest in Paediatric Ependymoma (2012) (0)
OS3.6 Development and validation of a DNA methylome-based predictor of meningioma recurrence and meningioma recurrence score (2018) (0)
Abstract 2182: Preclincial in vitro and in vivo combination therapies for mutant IDH1R132 tumors with BAY 1436032 (2019) (0)
Abstract B71: Molecular heterogeneity and novel oncogenic fusions in RELA- and YAP1-negative supratentorial ependymoma (2020) (0)
Tandem duplications of 7q34 and 3q25 in pilocytic astrocytoma result in RAF fusion genes (2010) (0)
LGG-11. REGULATION OF ONCOGENE-INDUCED SENESCENCE IN PILOCYTIC ASTROCYTOMA (2018) (0)
Abstract B075: Modeling response and resistance to immune checkpoint blockade in syngeneic mouse glioma (2019) (0)
Suppression of invasion-driving RGS 4 by radiation-enhanced mTOR inhibition optimizes antiangiogenesis (2017) (0)
LGG-13. PAPILLARY GLIONEURONAL TUMOR (PGNT) EXHIBITS A CHARACTERISTIC METHYLATION PROFILE AND MANDATORY FUSIONS INVOLVING PRKCA (2019) (0)
Nestin protein expression is an independent prognostic marker in ependymoma and discriminates WHO II ependymoma with poor outcome (2012) (0)
P06.06 A mutation-specific vaccine for Histone-3 K27M-mutated gliomas. (2017) (0)
P04.79 Cytotoxic T cells and their activation status are independent prognostic markers in meningiomas (2018) (0)
MPTH-23. LONG-TERM SURVIVAL WITH GLIOBLASTOMA IN THE ELDERLY (2016) (0)
INFORMING TREATMENT DECISIONS IN RELAPSED PEDIATRIC MALIGNANCIES USING NEXT-GENERATION DIAGNOSTICS (2014) (0)
Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma (2019) (0)
CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA (2018) (0)
High-dose radiation therapy using photons and carbon ion radiotherapy in patients with atypical and anaplastic meningiomas: Relevance of neuropathologic classification and therapeutic impact of a boost using of carbon ion radiotherapy. (2010) (0)
Abstract 1432: The heterogeneous genomic landscape of posterior fossa ependymoma (2012) (0)
Anaplastic pilocytic astrocytoma-an IDH-wildtype diffuse glioma characterized by a distinct DNA methylation profile and combined alterations in MAPK pathway genes, CDKN2A/B and ATRX (2017) (0)
Fibroblast Activation Protein specific PET: A novel imaging method for IDH-wildtype Glioblastomas and IDH-mutant Gliomas (2019) (0)
MNGI-28. CORRELATION OF METHYLATION CLASS AND GENETIC ALTERATIONS WITH PROGRESSION FREE SURVIVAL IN MENINGIOMA (2018) (0)
MYCN transcriptionally represses CD9 to trigger an invasion-metastasis cascade in neuroblastoma (2015) (0)
Targeting class I histone deacetylases in high risk medulloblastoma – analysis of molecular mechanisms and translational implications (2014) (0)
LG-27DKFZ-BT66 - A NOVEL PILOCYTIC ASTROCYTOMA MODEL FOR PRECLINICAL DRUG TESTING (2016) (0)
SOCIETY NEWS (2005) (0)
Abstract 1178: Identification of a novelBRAFfusion partner in pilocytic astrocytoma (2010) (0)
IMMU-49. CYTOTOXIC T CELLS AND THEIR ACTIVATION STATUS ARE INDEPENDENT PROGNOSTIC MARKERS IN MENINGIOMAS (2018) (0)
PO-0993: Genetic profiles of glioblastoma in proximity to the subventricular zone receiving chemoradiation (2016) (0)
Cancer esearch apeutics , Targets , and Chemical Biology e of LIM and SH 3 Protein 1 ( LASP 1 ) in the Metastatic R emination of Medulloblastoma (2010) (0)
Abstract LB-114: The INFORM personalized medicine study for high-risk pediatric cancer patients (2015) (0)
OS2.4 Expression and relevance of tumoral and stromal MHC class II in gliomas (2016) (0)
OS2.3 A mutation-specific vaccination approach for Histon H3.3 K27M-mutated gliomas (2016) (0)
Abstract 4699: Oncogenic fusion genes resulting from 7q34 deletions constitute a novel mechanism of MAPK pathway activation in pilocytic astrocytoma (2011) (0)
ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2018) (0)
Advances in Brief p53 Mutations Are Associated with 17p Allelic Loss in Grade II and Grade III Astrocytoma1 (2006) (0)
IMMU-54. THE ONCOMETABOLITE R-2-HYDROXYGLUTARATE SUPPRESSES THE INNATE IMMUNE MICROENVIRONMENT OF IDH1-MUTATED GLIOMAS VIA ARYL HYDROCARBON RECEPTOR SIGNALING (2018) (0)
Abstracts dscribing resources, technological and other developments (1991) (0)
A Vaccine Targeting Mutant IDH1 Induces Antitumor Immunity (S22.001) (2014) (0)
FISH-, expression- and methylation analyses of p16 correlated with response to TMZ-chemotherapy in patients with glioblastoma (2007) (0)
Recurrent MET fusion genes represent a druggable target in paediatric glioblastoma 1 2 (2016) (0)
Subject Index Vol. 7, 1997 (1997) (0)
360O Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link? (2020) (0)
Abstract 31: Subgroup-specific molecular alterations may explain the tremendous clinical heterogeneity of intracranial ependymoma (2010) (0)
SOCIETY NEWS (2005) (0)
Abstract 4277: Development and validation of a novel IDH1-mutant astrocyte cell line as a model for high-grade gliomas (2016) (0)
The Pediatric Brain Tumor Preclinical Testing Program: update and perspectives (2013) (0)
PATH-24. MOLECULAR SUBGROUPS OF ADULT EPENDYMAL TUMORS: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK (2017) (0)
Targeting differentially expressed histone deacetylases in Medulloblastoma – novel approach for treatment of high risk patients (2013) (0)
138 The MDM2 Inhibitor Nutlin-3 But Not the p53 Activator RITA Induces Loss-of-function p53 Mutations (2012) (0)
Abstracts for the committee on the genetic constitution of chromosome 14 (1991) (0)
PDTM-47. CHARACTERIZATION OF THE SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE IN PILOCYTIC ASTROCYTOMA AND ITS ROLE IN ONCOGENE-INDUCED SENESCENCE (2017) (0)
P09.18 Location-dependent prognostic factors and recurrence patterns in IDH wildtype glioblastoma. (2017) (0)
Abstracts for the committee on the genetic constitution of the X chromosome (Part 2 of 3) (2004) (0)
Promoter hypermethylation and aberrant expression of EMP3at 19q13.3 in oligodendrogliomas and astrocytomas (2007) (0)
INTEGRATED SYSTEMS AND TECHNOLOGIES 3206 Application of Raman Spectroscopy to Identify Microcalcifications and Underlying Breast Lesions at Stereotactic Core Needle Biopsy (2013) (0)
OS12.7.A Characterization of intra-tumoral heterogeneity and differential immune activation during malignant progression of meningiomas on single cell level (2021) (0)
O6.09PROSTAGLANDIN E RECEPTOR-4 ACTIVATION REGULATES TRYPTOPHAN METABOLISM IN HUMAN MALIGNANT GLIOMAS (2014) (0)
TBIO-10. PEDIATRIC TARGETED THERAPY 2.0: DEVELOPMENT OF PERSONALIZED PEDIATRIC ONCOLOGY (2018) (0)
Abstract 11: Advancing methylation profiling in neuropathology: Diagnosis and clinical management (2016) (0)
BIOM-59. TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK? (2020) (0)
Prognostic value of histopathologic grading of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheet tumour: need for a novel grading system? (2006) (0)
IMST-34. IMMUNOLOGICAL CHANGES DURING TUMOR PROGRESSION FROM PRIMARY TO RECURRENT GLIOBLASTOMA (2016) (0)
GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS (2019) (0)
Advances in Brief p 53 Mutations Are Associated with 17 p Allelic Loss in Grade II and Grade III Astrocytoma 1 (2006) (0)
Characterization of oncogene-induced senescence and the role of the senescence-associated secretory phenotype in pilocytic astrocytoma (2017) (0)
MUTATIONS IN THE IDH GENE (R13211) ARE NOT SUFFICIENT FOR EXPERIMENTAL GLIOMAGENESIS (2017) (0)
Opinion & Special Article: Glioma Classi ﬁ cation How to Interpret Molecular Markers in a Di ﬀ use Glioma Pathology Report (0)
In situ proximity ligation assay to evaluate presentation of a mutated CD4 epitope in human glioma tissue (2014) (0)
Utilization of a MAB for BRAF detection in papillary thyroid carcinoma (2012) (0)
Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme. (2015) (0)
Abstract 3646: (Epi-)genomic homogeneity in radiation-induced glioblastoma with recurrentPDGFRAamplification and loss ofCDKN2A/Bfollowing primary acute lymphatic leukemia and medulloblastoma (2019) (0)
INFORM: personalized pediatric oncology enters the clinic (2014) (0)
Expression of DNA methyl transferases and promoter methylation of tumor suppressor genes in astrocytomas (2008) (0)
Subject Index Vol. 58, 1991 (1991) (0)
Metronomic Chemotherapy With Daily Low Dose Temozolomide and Celecoxib in Elderly Patients With Newly Diagnosed Glioblastoma Multiforme: A Retrospective Analysis (2015) (0)
NIMG-09. NONINVASIVE PERFUSION IMAGING BIOMARKER OF MALIGNANT GENOTYPE IN ISOCITRATE DEHYDROGENASE MUTANT GLIOMAS (2019) (0)
SP-0656: Two years since the release of new WHO classification of CNS tumors: what has come up new and how to implement this? (2018) (0)
Abstracts for the committee on the mitochondrial genome (1991) (0)
Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma. (2018) (0)
Biological and clinical heterogeneity of MYCN-amplified (2012) (0)
MOLECULAR GENETIC DETERMINANTS OF LONG-TERM SURVIVAL WITH GLIOBLASTOMA (2014) (0)
2205 Preoperative chemoptherapy (CT) and twice daily radio-chemotherapy (HA RT/CT) versus preoperative chemotherapy alone in stage III non small cell lung cancer: Analysis of toxicity of a randomized trial (1999) (0)
Abstracts for the committee on clinical disorders and chromosomal deletion syndromes (1991) (0)
Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N{superscript 2}M{superscript 2}). (2016) (0)
Chelation of iron enhances invasion of glioblastoma cells (2007) (0)
Cancer Therapy : Clinical A Phase II , Randomized , Study of Weekly APG 101 þ Reirradiation versus Reirradiation in Progressive Glioblastoma (2014) (0)
Retraction: Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma (Molecular & cellular proteomics : MCP (2018) 17 11 (2132-2145)) (2019) (0)
MNGI-14. LOSS OF HISTONE H3K27me3 IDENTIFIES A SUBSET OF MENINGIOMAS WITH INCREASED RISK OF RECURRENCE (2018) (0)
Dysregulated expression of histone deacetylases in medulloblastoma - potential targets for selective inhibitor treatment (2013) (0)
SOCIETY NEWS (2004) (0)
SURG-16PROGNOSTIC VALUE OF THE EXTENT OF RESECTION AND IDH1 MUTATION STATUS IN WHO GRADE II ASTROCYTOMAS (2015) (0)
Identification of Two Molecular and Clinical Distinct Entities of Posterior Fossa Ependymoma (2011) (0)
Molecular Characterization of Radiation-induced Glioblastoma (2018) (0)
Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N2M2. (2018) (0)
P04.62 The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via aryl hydrocarbon receptor signaling (2018) (0)
Differential diagnostic impact of DNA methylation profiling on brain tumor classification (2019) (0)
P08.76 Anti-EGFL7 treatment as an add-on for glioma therapy (2016) (0)
Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD (2023) (0)
The Pediatric Brain Tumor Preclinical Testing Program: an update on the current status (2012) (0)
EG-09EPIGENETIC PROFILING REVEALS A CpG HYPERMETHYLATION PHENOTYPE (CIMP) ASSOCIATED WITH WORSE PROGRESSION-FREE SURVIVAL IN MENINGIOMA. (2014) (0)
OS6.4 Molecular classification of meningiomas across all histological subtypes and grades (2016) (0)
Abstracts for the committee on linkage and gene order (1991) (0)
Abstract IA11: Pediatric precision oncology programs in Germany and Europe (2018) (0)
Abstracts for the committee on the genetic constitution of chromosome 20 (1991) (0)
Abstractsfor the informatics committee (1991) (0)
THE GENETIC HETEROGENEITY OF POSTERIOR FOSSA EPENDYMOMA (2012) (0)
TBIO-07. ASSESSING THE UTILITY OF DNA METHYLATION PROFILING IN BRAIN TUMOR DIAGNOSTICS—THE PROSPECTIVE MNP2.0 STUDY (2018) (0)
ACTR-61. LONG-TERM ANALYSES OF THE NOA-08 RANDOMIZED PHASE III TRIAL (2018) (0)
Abstract 3094: Epigenetic classification of ependymal brain tumors across age groups (2014) (0)
OP08. MUTATIONS IN THE IDH GENE (R132H) ARE NOT SUFFICIENT FOR EXPERIMENTAL GLIOMAGENESIS (2017) (0)
892: Peripheral T cell responses in glioblastoma patients are associated with an improved survival (2014) (0)
Pediatrics Laboratory Research (2010) (0)
Histone Deacetylase 8i n NeuroblastomaTumorigenesis (2009) (0)
Abstracts for the committee on the genetic constitution of chromosome 18 (1991) (0)
Methylation among members of the PI3K/AKT/mTOR pathway in melanoma brain and extracerebral metastases. (2018) (0)
Abstract 4736: N-myc downstream regulated gene 1: A novel mediator of hypoxia-driven chemoresistance in glioblastoma (2012) (0)
Personalized pediatric oncology: Targeted Therapy and clinical feasibility (2013) (0)
Abstract 5560: PROX1 expression and function in malignant gliomas (2012) (0)
Brain metastases of gastro-oesophageal cancer (2013) (0)
Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup. (2019) (0)
GE-07DNA METHYLATION IN MEDULLOBLASTOMA AND MOLECULAR DIAGNOSTICS OF BRAIN TUMORS. (2015) (0)
Review Article - Oligodendrogliomas: Impact of molecular genetics on treatment (2005) (0)
Online Database Featuring Author , Key Word and Full-Text Search Guidelines on the Management of Low-grade Gliomas : EANO Task Force Report (2018) (0)
Index of GDB source ID numbers (1991) (0)
Abstracts for the comparative subcommittee on human and mouse homologies (1991) (0)
TB-14THE INFORM PERSONALIZED MEDICINE STUDY - NEW MOLECULAR INSIGHTS INTO RELAPSED PEDIATRIC BRAIN TUMORS (2016) (0)
THE CHROMOSOME 19q GLIOMA TUMOR SUPPRESSOR GENE: DELETION MAPPING AND CANDIDATE GENES (1995) (0)
Oncogene-induced senescence and the senescence-associated secretory phenotype in pilocytic astrocytoma (2017) (0)
Radiogenomic rCBV-imaging visualizes the moleculare signature of IDH-mutant and wildtype gliomas (2016) (0)
[Asthma, nonspecific bronchial hyperreactivity. Asking knowledgable experts]. (2006) (0)
P05.51 Prognostic impact of genetic alterations and methylation class in meningioma (2018) (0)
MNGI-02. PREOPERATIVE EMBOLIZATION OF MENINGIOMA: INFERIOR NEUROLOGICAL OUTCOME, INCREASED RISK OF CARDIOVASCULAR COMPLICATIONS AND SHORTER TIME TO RECURRENCE? (2017) (0)
Abstract 1889: Next-generation neuropathology - Improving diagnostic accuracy for brain tumors using DNA methylation array-based molecular profiling (2014) (0)
P09.09 Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas (2016) (0)
CB-058. REGULATION OF CANCER PROMOTING TRYPTOPHAN CATABOLISM IN GLIOBLASTOMA BY THE GLUCOCORTICOID RECEPTOR (2013) (0)
Abstractsfor the DNA committee (1991) (0)
ANGI-08RADIOGENOMIC rCBV-IMAGING VISUALIZES THE DISTINCT ANGIOGENESIS TRANSCRIPTOME SIGNATURES OF IDH MUTANT AND WILD-TYPE GLIOMAS. (2015) (0)
Featuring Author , Key Word and Full-Text Search Guidelines on the Management of Low-grade Gliomas : EANO Task Force Report (2016) (0)
TRTH-09. PTT2.0: DEVELOPING PERSONALIZED PEDIATRIC ONCOLOGY (2017) (0)
NIMG-51. RADIOLOGIC PHENOTYPES ARE TREATMENT SPECIFIC AND ASSOCIATED WITH SURVIVAL - EXPLORATORY ANALYSIS OF EORTC 26101 (2017) (0)
Abstracts for the committee on the genetic constitution of chromosome 5 (1991) (0)
SOCIETY NEWS (2005) (0)
The Pediatric Brain Tumor Preclinical Testing Program: evaluation of an individualized molecular treatment approach (2011) (0)
LGG-20. MOLECULARLY-DEFINED DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) COMPRISES TWO SUBGROUPS WITH DISTINCT CLINICAL AND GENETIC FEATURES (2018) (0)
Abstract 138: Solid papillary carcinoma with reverse polarization are driven by IDH2 and PI3K pathway mutations (2016) (0)
DNA methylation profiles of angiosarcoma subtypes (2019) (0)
Abstracts for the committee on the genetic constitution of chromosome 8 (1991) (0)
Paul Kleihues (1936–2022), neuropathology innovator and entrepreneur (2022) (0)
A Model for the Molecular Pathogenesis of Astrocytic Gliomas (1996) (0)
Abstracts for the committee on the genetic constitution of chromosome 21 (1991) (0)
OS2.2 Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial (2018) (0)
Oncogene Complementation in Fetal Brain Transplants1 (2006) (0)
Abstract 3453: Induction of differentiation in high-risk ependymoma stem-like cells by treatment with the HDAC inhibitor Vorinostat (2011) (0)
Mutant IDH1R132H bears a mutation-specific CD4 T cell epitope suitable for vaccination of human CNS tumors (2014) (0)
P04.52 Spontaneous intratumoral T cell responses against glioblastoma-associated antigens (2018) (0)
IMMU-41. HIGH-THROUGHPUT RETRIEVAL OF THERAPEUTIC T CELL RECEPTORS FROM GLIOMA (2020) (0)
Abstract PR15: The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via aryl hydrocarbon receptor signaling (2019) (0)
Molecular analysis of meningioma increases prognostic power: A methylation-based classification and grading system (2018) (0)
Gliomas - ReadingSample (2016) (0)

This paper list is powered by the following services:

Andreas Von Deimling's Academic­Influence.com Rankings

Andreas Von Deimling's Degrees

Why Is Andreas Von Deimling Influential?

Andreas Von Deimling's Published Works

Published Works

Andreas Von Deimling's AcademicInfluence.com Rankings